NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
16/12/2021
Voltar para busca
Dado oficial do USPTO
EXPRESSF+
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
21/04/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
19/04/1999
Data de registro
20/06/2000
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/12/2021
Última transação
21/04/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
07/04/1999
Primeiro uso no comércio
07/04/1999
Código do desenho
1
Tipo de titular
03
Localização do titular
Meriden, CT, US
Examinador
SINGLETON, RUDY
Unidade examinadora
L90
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
P. C. (pessoa física)
Representantes
Karen Lim FROSS ZELNICK LEHRMAN & ZISSU, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Cell lines for use in the production of recombinant proteins for medical and clinical use and cells for medical or clinical useincluding an insect linea baculovirus-suspectible insect cell linea spodoptera frugiperda cell line having one or more of the following characteristics - cells which are genetically and morphologically distinct from the parent of Sf9 cellscells which replicate in serum-free mediumcells which grow as a suspension of single cells without significant clumpingcells which grow exponentially with a cell doubling time of 18 to 24 hourscells which can be passed continuously for at least 6 months while maintaining a high level of viability (>98%)cells which are highly permissive to infection with californica npv baculoviruses resulting in high-titered virus stockscells which are useful for the production of recombinant DNA gene cell products following infection with baculovirus vectorscells which are useful for the production and plaque-isolation of genetically engineered baculovirus cells which meet the general identity and safety requirements for cells set by government regulatory agenciescells which are suitable for the manufacture of biological pharmaceutical products following cGMP standards
Classe 5
Cell lines for use in the production of recombinant proteins for scientificlaboratory and medical research and cells for research of a scientificlaboratory or medical natureincluding an insect linea baculovirus-suspectible insect cell linea spodoptera frugiperda cell line having one or more of the following characteristics - cells which are genetically and morphologically distinct from the parent Sf9 cellscells which replicate in serum-free mediumcells which grow as a suspension of single cells without significant clumpingcells which grow exponentially with a cell doubling time of 18 to 24 hourscells which can be passed continuously for at least 6 months while maintaining a high level of viability (>98%)cells which are highly permissive to infection with californica npv baculoviruses resulting in high-titered virus stockscells which are useful for the production of recombinant DNA gene cell products following infection with baculovirus vectorscells which are useful for the production and plaque-isolation of genetically engineered baculovirus cells which meet the general identity and safety requirements for cells set by government regulatory agenciescells which are suitable for the manufacture of biological pharmaceutical products following cGMP standards
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
16/12/2021
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
16/12/2021
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
16/12/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/12/2021
PCGR
PETITION TO DIRECTOR GRANTED
03/12/2021
APET
ASSIGNED TO PETITION STAFF
30/11/2021
TPDR
TEAS PETITION TO DIRECTOR RECEIVED
21/04/2021
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
01/04/2021
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
25/01/2021
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
15/10/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
30/09/2020
E89R
TEAS SECTION 8 & 9 RECEIVED
20/08/2020
CORV
REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
08/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/12/2019
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
20/06/2019
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
19/09/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/01/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/01/2018
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
02/08/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
11/10/2010
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
11/10/2010
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
21/05/2010
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
21/05/2010
E89R
TEAS SECTION 8 & 9 RECEIVED
18/05/2010
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
01/03/2007
PLGL
ASSIGNED TO PARALEGAL
20/02/2007
815F
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
19/12/2006
E815
TEAS SECTION 8 & 15 RECEIVED
19/12/2006
CFIT
CASE FILE IN TICRS
23/03/2006
R.PR
REGISTERED-PRINCIPAL REGISTER
20/06/2000
PUBO
PUBLISHED FOR OPPOSITION
28/03/2000
NPUB
NOTICE OF PUBLICATION
25/02/2000
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/01/2000
IUAA
USE AMENDMENT ACCEPTED
28/01/2000
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/10/1999
CNRT
NON-FINAL ACTION MAILED
16/09/1999
DOCK
ASSIGNED TO EXAMINER
03/09/1999
DOCK
ASSIGNED TO EXAMINER
20/08/1999
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
30/07/1999
IUAF
USE AMENDMENT FILED
30/06/1999
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EXPRESSF+ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.